Clinically significant grapefruit juice-drug interactions

Nutrition Today

Volumn 43, Issue 1, 2008, Pages 19-28

  McCloskey, William W ^a   Zaiken, Kathy ^b,c   Couris, R Rebecca ^d  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b Department of Pharmacy Practice

^c HARVARD VANGUARD MEDICAL ASSOCIATES   (United States)

^d Harvard Vanguard Medical Associates Kenmore Facility ^*

Author keywords

[No Author keywords available]

Indexed keywords

EID: 39149104616     PISSN: 0029666X     EISSN: 15389839     Source Type: Journal    
DOI: 10.1097/01.NT.0000303302.08847.02     Document Type: Review

References (68)

1. Bailey DG, Spence JD, Edgar B, et al. Ethanol enhances the hemodynamic effects of felodipine. Clin Invest Med. 1989;12:357-362.
2. Mertens-Talcott SU, Zadezensky WV, De Castro WV, et al. Grapefruit-drug interactions: can interactions with drugs be avoided? J Clin Pharmacol. 2006;46:1390-1416.
3. Bressler R. Grapefruit juice and prescription drug interactions. Geriatrics. 2006;61:12-18.
4. Cerda JJ, Robbins FL, Burgin CW, et al. The effects the grapefruit pectin on patients at risk for coronary heart disease without altering diet or lifestyle. Clin Cardiol. 1988;11:589-594.
5. Kane GC, Lipsky JJ. Drug-grapefruit interactions. Mayo Clin Proc. 2000;75:933-942.
6. Guthrie N, Carroll KK. Inhibition of mammary cancer by citrus flavonoids. Adv Exp Med Biol. 1998;439:227-236.
7. Kawaii S, Tomono Y, Katase E, et al. Antiproliferative activity of flavonoids on several cancer cell lines. Biosci Biotechnol Biochem. 1999;63:896-899.
8. Bailey DG, Malcolm J, Arnold O, Spence JD. Grapefruit juice-drug interactions. Br J Clin Pharmacol. 1998;46:101-110.
9. Lundahl J, Regardh CG, Edgar B, et al. Effects of grapefruit ingestion-pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men. Eur J Clin Pharmacol. 1997;52:139-145.
10. Uno T, Ohkubo T, Sugawara K, et al. Effects of grapefruit juice on the stereo selective disposition of nicardipine in humans: evidence or dominant presystemic elimination at the gut site. Eur J Clin Pharmacol. 2000;56:643-649.
11. Huang SM, Hall SD, Watkins P, et al. Drug interactions with herbal products and grapefruit juice: a conference report. Clin Pharmacol Ther. 2004;75:1-12.
12. Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, et al. Mechanisms of enhanced bioavailability of CYP3A4 substrates by grapefruit constituents: decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos. 1997;25:1228-1233.
13. Wang EJ, Casciano CN, Clement RP, et al. Inhibition of P-glycoprotein transport function by grapefruit juice psoralen. Pharm Res. 2001;18:432-438.
14. Paine MF, Criss Ab, Watkins PB. Two major grapefruit juice components differ in time to onset of intestinal CYP3A4 inhibition. J Pharmacol Exp Ther. 2005;312:1151-1160.
15. Fukuda K, Ohta F, Yamazoe Y. Grapefruit component interacting with rat and human P450 CYP3A: possible involvement of non-flavonoid components in drug interaction. Biol Pharm Bull. 1997;20:560-564.
16. Fuhr U, Klittich K, Staib AH. Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man. Br J Clin Pharmacol. 1993;35:431-436.
17. Edwards DJ, Bernier SM. Naringin and naringenin are not the primary CYP3A inhibitors in grapefruit juice. Life Sci. 1996;59:1025-1030.
18. Fukuda K, Gua L, Ohashi N, et al. Amounts and variation in grapefruit juice of the main components causing grapefruit-drug interaction. J Chromatogr. 2000;741:195-203.
19. Ho PC, Saville DJ, Coville PF, et al. Content of CYP3A4 inhibitors, naringin, naringenin and bergapten in grapefruit and grapefruit juice products. Pharm Acta Helv. 2000;74:379-385.
20. Bailey DG, Dresser GK. Interactions between grapefruit juice and cardiovascular drugs. Am J Cardiovasc Drugs. 2004;4:281-297.
21. Buxton ILO. Pharmacokinetics and pharmacodynamics: the dynamics of drug absorption, distribution, action and elimination. In: Bruton L, Lazo J, Parker K, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11th ed. New York, NY: McGraw-Hill; 2005:1-39.
22. Slaughter RL, Edwards DJ. Recent advances: the cytochrome P450 enzymes. Ann Pharmacother. 1995;29:619-624.
23. Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet. 2002;360:1155-1162.
24. Nebert DW, Adesnick M, Coon MJ, et al. The P450 gene superfamily: recommended nomenclature. DNA. 1987;6:1-11.
25. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med. 2005;352:2211-2221.
26. Zhang QY, Dunbar D, Ostrowska A, et al. Characterization of human small intestinal cytochromes P-450. Drug Metab Dispos. 1999;27:L804-L809.
27. Rogers JF, Nafziger AN, Bertino JS. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med. 2002;113:746-750.
28. Cupp MJ, Tracy T. Cytochrome P450: new nomenclature and clinical implications. Am Fam Phys. 1998;57:107-116.
29. Van der Weide J, Steijns LS. Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology. Ann Clin Biochem. 1999;36:722-729.
30. Greenblatt DJ, Patki KC, von Moltke LL, Shader RI. Drug interactions with grapefruit juice: an update. J Clin Psychopharmacol. 2001;21:357-359.
31. Lilja JJ, Kivisto KT, Backman JT, Neuvonen PJ. Effect of grapefruit juice dose on grapefruit juice-triazolam interaction: repeated consumption prolongs triazolam half-life. Eur J Clin Pharmacol. 2000;56:411-415.
32. Veronese ML, Gillen LP, Burke JP, et al. Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice. J Clin Pharm. 2003;43:831-839.
33. Culm-Merdek KE, von Moltke LL, Gan L, et al. Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir. Clin Pharmacol Ther. 2006;79:243-254.
34. Lin H, Kent UM, Hollenberg PF. The grapefruit juice effect is not limited to cytochrome P450(P450) 3A4: evidence for bergamotten-dependent inactivation, heme destruction, and covalent binding to protein in P450s 2B6 and 3A5. J Pharmacol Exp Ther. 2005;313:154-164.
35. Lown KS, Bailey DG, Fontana RJ, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest. 1997;99(10):2545-2553.
36. Saito M, Hirata-Koizumi M, Matsumoto M, et al. Undesirable effects of citrus juice on the pharmacokinetics of drugs: focus on recent studies. Drug Saf. 2005;28:677-694.
37. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Time course of recovery of cytochrome P450 3A function after single doses of grapefruit juice. Clin Pharmacol Ther. 2003;74:121-129.
38. Hare JT, Elliott DP. Grapefruit juice and potential drug interactions. Consult Pharm. 2003;18:466-472.
39. Bailey DG, Dresser GK, Bend JR. Bergamottin, lime juice, and red wine as inhibitors of cytochrome P450 3A4 activity: comparison with lime juice. Clin Pharmacol Ther. 2003;73:529-537.
40. Malhotra S, Bailey DG, Paine MF, Watkins PB. Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furanocoumarins. Clin Pharm Ther. 2001;69:14-23.
41. Paine MF, Widmer WW, Hart HL, et al. A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction. Am J Clin Nutr. 2006;83:1097-1105.
42. Leveille-Webster CR, Arias IM. The biology of the P-glycoproteins. J Membr Biol. 1995;143:89-102.
43. Edwards DJ, Fitzsimmons ME, Schuetz EG, et al. 6,7-Dihydroxybergamotten in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein. Clin Pharm Ther. 1999;65:237-244.
44. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet. 2003;42:59-98.
45. Parker RB, Yates CR, Soberman JE, Laizure SC. Effects of grapefruit juice on intestinal P-glycoprotein: evaluation using digoxin in humans. Pharmacotherapy. 2003;23:979-987.
46. Dresser GK, Bailey DG, Leake BF, et al. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther. 2002;71:11-20.
47. Dreier JP, Endres M. Statin-associated rhabdomyolysis triggered by grapefruit consumption. Neurology. 2004;62:670.
48. Anonymous. Drug interactions with grapefruit juice. Med Lett Drugs Ther. 2004;46(1173):2-4.
49. Libersa CC, Brique SA, Motte KB, et al. Dramatic inhibition of amiodarone metabolism induced by grapefruit juice. Br J Clin Pharmacol. 2000;49:373-378.
50. Codarone product information. Philadelphia, PA: Wyeth Pharmaceuticals Inc; September 2006.
51. Garg SK, Kumar N, Bhargava VK, et al. Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy. Clin Pharmacol Ther. 1998;64:286-288.
52. Oesterheld J, Kallepalli BR. Grapefruit juice and clomipramine: shifting the metabolic ratios. J Clin Psychopharmacol. 1997;17:62-63.
53. Penzak SR, Gubbins PO, Gurley BJ, et al. Grapefruit juice decreases the systemic bioavailability of intraconazole in healthy volunteers. Ther Drug Monit. 1999;21:304-309.
54. Banfield C, Gupta S, Marino M, et al. Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratidine. Clin Pharmacokinet. 2002;41:311-318.
55. Allegra product information. Bridgewater, NJ: Sanofi-Aventis US, LLC; October 2006.
56. Reif S, Nicolson MC, Bisset D, et al. Effect of grapefruit juice intake on etoposide bioavailability. Eur J Clin Pharmacol. 2002;58:491-494.
57. Lija JJ, Kivisto KT, Backman JT, et al. Grapefruit substantially increases plasma concentrations of buspirone. Clin Pharmacol Ther. 1998;64:655-660.
58. Ozdemir M, Aktan Y, Boydag BS, et al. Interaction between grapefruit juice and diazepam in humans. Eur J Drug Metab Pharmacokinet. 1998;23:55-59.
59. Lundahl J, Regardh CG, Edgar B, et al. Effects of grapefruit juice ingestion: pharmacokinetics and pharmacodynamics of intravenously and orally administered felodipine in healthy men. Eur J Clin Pharmacol. 1997;52:139-145.
60. Edgar B, Bailey D, Bergstrand R, et al. Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine and its potential clinical relevance. Eur J Clin Pharmacol. 1992;42:313-317.
61. Uno T, Ohkudbo T, Sugawara K, et al. Effects of grapefruit juice on the stereoselective disposition of nicardipine in humans: evidence for dominant presystemic elimination at the gut site. Eur J Clin Pharmacol. 2000;56:643-649.
62. Fuhr U, Maier-Bruggemann A, Blume H, et al. Grapefruit juice increases oral nimodipine bioavailability. Int J Clin Pharmacol Ther. 1998;36:126-132.
63. Rashid J, McKinstry C, Renwick AG, et al. Quecetin, an in vitro inhibitor of CYP3A, does not contribute to the interaction between nifedipine and grapefruit juice. Br J Clin Pharmacol. 1993;36:460-463.
64. Bailey DG, Arnold JM, Strong HA, et al. Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics. Clin Pharmacol Ther. 1993;54:589-594.
65. Lee M, Min DI. Determination of sildenafil citrate in plasma by high-performance liquid chromatography and a case for the potential interaction of grapefruit juice with sildenafil citrate. Ther Drug Monit. 2001;23:21-26.
66. Ioannides-Demos LL, Christophidis N, Ryan P, et al. Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases. J Rheumatol. 1997;24:49-54.
67. Benmebarek M, Devaud C, Gex-Fabry M, et al. Effects of grapefruit juice on the pharmacokinetics the enantiomers of methadone. Clin Pharmacol Ther. 2004;76:55-63.
68. Kupferschmidt HH, Fattinger KE, Ha HR, et al. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol. 1998;45:355-359.